J 2023

Effectiveness of ICD therapy in real clinical practice. The Olomouc ICD Registry

TABORSKY, Milos, Tomas SKALA, Marian FEDORCO, Vlastimil DOUPAL, Ingrid SOVOVA et. al.

Basic information

Original name

Effectiveness of ICD therapy in real clinical practice. The Olomouc ICD Registry

Authors

TABORSKY, Milos (203 Czech Republic), Tomas SKALA (203 Czech Republic, guarantor), Marian FEDORCO (203 Czech Republic), Vlastimil DOUPAL (203 Czech Republic), Ingrid SOVOVA (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Klára BENEŠOVÁ (203 Czech Republic, belonging to the institution), Monika BEZDEKOVA (203 Czech Republic), Marek VICHA (203 Czech Republic), Josef DANEK (203 Czech Republic) and Josef KAUTZNER (203 Czech Republic)

Edition

Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2023, 1213-8118

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30230 Other clinical medicine subjects

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 0.900 in 2022

RIV identification code

RIV/00216224:14110/23:00129947

Organization unit

Faculty of Medicine

UT WoS

000733638200001

Keywords in English

implantable cardioverter-defibrillator; heart failure; primary prevention; time to shock; sppropriate shock; mortality

Tags

Tags

International impact, Reviewed
Změněno: 26/1/2024 09:48, Mgr. Tereza Miškechová

Abstract

V originále

Background. Clinical parameters linked to a low benefit of ICD implantation and increased mortality risks are needed for an individualized assessment of potential benefits and risks of ICD implantation. Methods. Analysis of a prospective registry of all patients hospitalized from 2009 to 2019 in a single centre for a first Results. A total of 2,681 patients were included in the registry. Until the end of follow-up (38.4 +/- 29.1 months), 682 (25.4%) patients died. The one-year mortality in all patients, the one-year CV mortality, the three-year mortality in all patients, and the three-year CV mortality were 7.8%, 5.7%, 20.6%, and 14.8%, respectively. There was a statistically significant difference when the subgroups were compared according to the type of cardiomyopathy. No significant difference was found between primary and secondary prevention and between the types of devices. Male gender, age >= 75 years, diabetes mellitus, and atrial fibrillation were associated with a significantly increased mortality risk. Conclusion. In an analysis of a long-term follow-up of 2,681 ICD patients, we found no mortality difference between patients with ischemic or non-ischemic cardiomyopathy and in the device type. A higher mortality risk was found in men, patients older than 75 years, diabetics, and those with atrial fibrillation.